10 September 2018 - Cipher Pharmaceuticals today announced it received Health Canada approval of Xydalba (dalbavancin hydrochloride), the first and only one-dose treatment option for acute bacterial skin and skin structure infections (ABSSSI) in adults and available in Canada.

Cipher acquired Xydalba through the acquisition of the Canadian business portfolio of Cardiome Pharma Corporation, which was completed in May 2018.

Read Cipher Pharmaceuticals press release